“Glioblastoma – Pipeline Insight, 2021,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Glioblastoma: Overview Glioblastoma, also known as Glioblastoma Multiforme is a fast growing glioma that develops from star shaped glial cells (astrocytes) that supports the health of nerve cells in the brain. A grading system from I to IV defines the rate of tumor growth grade I indicating slow growth and grade IV indicating rapid growth. The exact cause of glioblastoma is unknown. However, there are factors that can influence the risk of glioblastoma. Suspected individuals with glioblastoma undergoes physical and neurological examination. Sophisticated imaging techniques can very accurately pinpoint the location of brain tumors. Diagnostic tools include computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI). Treating glioblastoma is difficult due to several complicating factors. Treatment options include a combination of surgery, radio therapy, chemotherapy, and alternating electric fields therapy.
"Glioblastoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioblastoma pipeline landscape is provided which includes the disease overview and Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights - The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Glioblastoma.
Glioblastoma Emerging Drugs Chapters This segment of the Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glioblastoma Emerging Drugs - Enzastaurin Hydrochloride: Denovo Biopharma
Enzastaurin Hydrochloride is an anti-timor drug being developed by Denovo Biopharma. Enzastaurin Hydrochloride has received orphan drug designation for the treatment of Glioblastoma. Denovo acquired global rights to enzastaurin from Lilly, including development, production and commercialization. The drug is being studied in phase III stage of development for the treatment of Glioblastoma.
- Marizomib: Celgene
Marizomib is naturally occurring chemical compound, isolated from marine bacteria. This intravenously administered drug binds to and inhibits a certain protein complex involved in degradation of unneeded or damaged proteins. The subsequent abnormal accumulation of proteins is thought to inhibit tumor cell growth by signaling to the cell to stop dividing and undergo cell death. Clinical trials for Marizomib are being conducted by Celgene Corporation for the Glioblastoma. Marizomib has also recieved orphan drug designation for the treatment of patients with Glioblastoma.
- 2-OHOA: Laminar Pharmaceutcals
2-OHOA (2-hydroxyoleic acid) is a synthetic derivative of oleic acid which can be taken orally and is able to reach cells in the brain by crossing the Blood Brain Barrier. This drug alters the composition of the plasma membrane in cancer cells, reducing the activity of membrane-associated signaling proteins that are known to promote tumor growth. The drug is being studied in phase II/III for the treatment of Glioblastoma.
- ONC-201: Oncotherapeutics
ONC201 is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that is able to penetrate the blood-brain-barrier effectively. The drug antagonizes specific dopamine receptors that are highly expressed in tumors of the brain, particularly those that occur in its midline structures. ONC-201 is being studied in phase II for the Glioblastoma.
- NVX-108: NuvOx LLC
NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy and the clinical trials are being conducted for NVX-108 in phase II for Glioblastoma.
- CAN008: CANbridge Life Sciences
CAN008 is a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to the CD95 ligand (CD95L). It has a unique dual mechanism of action, which can inhibit the invasive growth of tumor cells and the programmed cell death of T cells, and repair immune function. CANbridge has initiated a aphase II trials for the CAN008 for the treatment of patients with Glioblastoma.
- INO5401: Inovio Pharmaceuticals
INO-5401 encodes for INOVIO’s SynCon antigens for hTERT, WT1, and PSMA, and has the potential to be a powerful cancer immunotherapy in combination with checkpoint inhibitors. The drug is being studied in phase II clinical trials in collaboration with Regeneron Pharmaceuticals.
- CC-90010: Celgene Corporation
CC-90010 is a reversible oral Bromodomain and Extra-Terminal (BET) inhibitor. Bromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of genes involved in oncogenesis. CC-90010 clinical trials are being carried out by Celgene in phase I/II stage of development for the treatment of Glioblastoma.
- Temeferon: Genenta Science
Temferon is an Investigational Advanced Therapy Medicinal Product (ATMP) consisting of autologous CD34+-TEM enriched Hematopoietic Stem and Progenitor Cells (HSPC) transduced with a Lentiviral Vector (LV) encoding the human interferon-?2 (IFN-?2) gene. Temferon is being studied in phase I/II clinical trials for the treatment of patients with Glioblastoma.
Further product details are provided in the report……..
Glioblastoma: Therapeutic Assessment This segment of the report provides insights about the different Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Glioblastoma
There are approx. 150+ key companies which are developing the therapies for Glioblastoma. The companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo Biopharma.
This report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
- Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Small molecule
• Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Glioblastoma: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glioblastoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioblastoma drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Glioblastoma drugs?
• How many Glioblastoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioblastoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioblastoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glioblastoma and their status?
• What are the key designations that have been granted to the emerging drugs?
Our reports have been used by over 10K customers, including:
Colon Carcinoma (Oncology) - Drugs in Development, 2021 Summary Colon Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete...
High-Grade Glioma (Oncology) - Drugs in Development, 2021 Summary High-Grade Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma,...
Non-Small Cell Lung Carcinoma (Oncology) - Drugs in Development, 2021 Summary Non-Small Cell Lung Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics...
Liposarcoma (Oncology) - Drugs in Development, 2021 Summary Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis...
Ependymoma (Oncology) - Drugs in Development, 2021 Summary Ependymoma (Oncology) - Drugs in Development, 2021 provides an overview of the Ependymoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ependymoma, complete with analysis...
Plexiform Neurofibroma (Non Malignant Disorders) - Drugs in Development, 2021 Summary Plexiform Neurofibroma (Non Malignant Disorders) - Drugs in Development, 2021 provides an overview of the Plexiform Neurofibroma pipeline landscape. The report provides comprehensive information on the therapeutics...
Pancreatic Ductal Carcinoma (Oncology) - Drugs in Development, 2021 Summary Pancreatic Ductal Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Pancreatic Ductal Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under...
Refractory Medulloblastoma (Oncology) - Drugs in Development, 2021 Summary Refractory Medulloblastoma (Oncology) - Drugs in Development, 2021 provides an overview of the Refractory Medulloblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development...